630 related articles for article (PubMed ID: 28699667)
21. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
22. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
23. Smoldering mantle cell lymphoma.
Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
[TBL] [Abstract][Full Text] [Related]
24. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
[TBL] [Abstract][Full Text] [Related]
25. Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases.
Veselá P; Tonar Z; Sálek D; Vokurka S; Trněný M; Kodet R; Moulis M; Kašparová P; Vernerová Z; Velenská Z; Stříteský J; Michal M; Boudová L
Virchows Arch; 2014 Nov; 465(5):587-97. PubMed ID: 25048573
[TBL] [Abstract][Full Text] [Related]
26. Current and emerging treatment options for mantle cell lymphoma.
Fakhri B; Kahl B
Ther Adv Hematol; 2017 Aug; 8(8):223-234. PubMed ID: 28811872
[TBL] [Abstract][Full Text] [Related]
27. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.
Gallucci Figorelle L; Galvão PT; de Lima FMR; Marimon P; Pentagna N; Milito C; Schaffel R; Carneiro K
Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):433-445. PubMed ID: 38641485
[TBL] [Abstract][Full Text] [Related]
28. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
29. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
[TBL] [Abstract][Full Text] [Related]
30. Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment.
Jain AG; Chang CC; Ahmad S; Mori S
Curr Treat Options Oncol; 2019 Nov; 20(12):85. PubMed ID: 31776787
[TBL] [Abstract][Full Text] [Related]
31. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
32. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
33. PAX5 aberrant expression incorporated in MIPI-SP risk scoring system exhibits additive value in mantle cell lymphoma.
Zhang X; Han Y; Nie Y; Jiang Y; Sui X; Ge X; Liu F; Zhang Y; Wang X
J Mol Med (Berl); 2023 May; 101(5):595-606. PubMed ID: 37126184
[TBL] [Abstract][Full Text] [Related]
34. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype.
Bernard M; Gressin R; Lefrère F; Drénou B; Branger B; Caulet-Maugendre S; Tass P; Brousse N; Valensi F; Milpied N; Voilat L; Sadoun A; Ghandour C; Hunault M; Leloup R; Mannone L; Hermine O; Lamy T
Leukemia; 2001 Nov; 15(11):1785-91. PubMed ID: 11681422
[TBL] [Abstract][Full Text] [Related]
35. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
[TBL] [Abstract][Full Text] [Related]
36. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M; Kluin-Nelemans HC; Beà S; Klapper W; Vogt N; Delfau-Larue MH; Hutter G; Cheah C; Chiappella A; Cortelazzo S; Pott C; Hess G; Visco C; Vitolo U; Klener P; Aurer I; Unterhalt M; Ribrag V; Hoster E; Hermine O;
Leuk Lymphoma; 2013 Apr; 54(4):699-707. PubMed ID: 23020649
[TBL] [Abstract][Full Text] [Related]
37. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
38. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
[TBL] [Abstract][Full Text] [Related]
39. Treatment strategies in mantle cell lymphoma.
Maddocks K; Blum KA
Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
[TBL] [Abstract][Full Text] [Related]
40. Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan.
Wang YH; Yu SC; Ko BS; Yang YT; Yao M; Tang JL; Huang TC
Int J Hematol; 2020 Sep; 112(3):385-394. PubMed ID: 32519171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]